SecBot SecBot

OPK

OPKO HEALTH, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000944809 Biotech & Drug Discovery
$1.62 −0.06 (−3.57%)
Nov 16 4:00 PM ET · prev $1.68
Market cap
$1.2B
Small cap
Consensus
Buy
80% Buy or better · 10 analysts
Median target
$3.00
+85% · range $2.25–8.50
1 year
+27.6%
from $1.27 · Nov 17
30 days
+0.6%
from $1.61
52-week range
$1.10–1.77
−8% from high · low Mar 30
Avg volume 20D
3.42M
Nov 5 spike 9.79M
Short interest
32.85M
≈4.4% of shares · −3.4%
Days to cover
9.2
at average volume
Insider net
−$13.2K
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $11.3K at an average $1.14. 1 insider sold $24.6K. Price is 43% above their cost.

  • InstitutionsBULLISH

    Q3 2026: 21 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    8 of 10 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −3.4% to 32.85M shares. 9.2 days to cover, ≈4.4% of shares.

  • TrendUPTREND

    1% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGTRIM2,917,608$4.7M
Clearstead Advisors, LLCADD1,133,142$1.8M
JPMORGAN CHASE & CODOUBLED812,817$1.3M
Connor, Clark & Lunn Investment Management Ltd.ADD765,284$1.2M
BARCLAYS PLCDOUBLED248,608$400.3K
Squarepoint Ops LLCDOUBLED212,144$341.6K
BNP PARIBAS FINANCIAL MARKETSDOUBLED143,283$230.7K
GROUP ONE TRADING LLCADD90,125$145.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 80% rate it Buy or better
Strong Buy3Buy5Hold2Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +85%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 16, 2026Piper Sandler
REITERATE
REITERATEOverweight
Oct 16, 2026Barrington Research
UPGRADE
UPGRADEOutperform

Washington

Corporate Lobbying

4 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$11.3K
bought · 1 insider
$24.6K
sold · 1 insider
+42.7%
vs their $1.14 cost
DateInsiderTypeValue
Nov 5, 2026
PAGANELLI JOHN A
Director
Nov 5, 2026
SELL$16.7K
Nov 5, 2026
PAGANELLI JOHN A
Director
Nov 5, 2026
SELL$7.9K
Jul 24, 2026
Rubin Steven D
Executive VP-Administration
Jul 24, 2026
TAX W/H$65.0K
Jul 24, 2026
Logal Adam
Sr. Vice President, CFO
Jul 24, 2026
TAX W/H$65.0K
Jun 18, 2026
PFENNIGER RICHARD C JR
Director
Jun 18, 2026
AWARD60,000 sh
Jun 18, 2026
Lachman Prem A
Director
Jun 18, 2026
AWARD30,000 sh
Jun 18, 2026
Yu Alice Lin-Tsing
Director
Jun 18, 2026
AWARD30,000 sh
Jun 18, 2026
UPPALURI SUBBARAO V
Director
Jun 18, 2026
AWARD80,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
32,849,261
shares short
-3.4%
vs prior settlement
9.2
days to cover
≈4.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 5, 2026 Insider
PAGANELLI JOHN A sold 9,175 shares
Director @ $1.82 ($16.7K)
Nov 5, 2026 Insider
PAGANELLI JOHN A sold 4,426 shares
Director @ $1.78 ($7.9K)
Nov 4, 2026 SEC
OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M consensus which included…
8-K · Impact 6/10
Nov 4, 2026 SEC
OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M consensus which included…
PRESS-RELEASE · Impact 6/10
Nov 4, 2026 Earnings
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
Conference Call to Begin Today at 4:30 p.m. ET Conference Call to Begin Today at 4:30 p.m. ET
Oct 15, 2026 SEC
OPKO Health (OPK) has agreed to sell its BioReference clinical and anatomic pathology laboratory testing business…
8-K · Impact 7/10
Sep 30, 2026 Inst.
UBS Group AG · TRIM
2,917,608 shares ($4.7M)
Sep 30, 2026 Inst.
Clearstead Advisors, LLC · ADD
1,133,142 shares ($1.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

7 filings · 3 press releases · 1 bullish · 0 bearish · 1 mixed · 5 neutral
All OPK filing & press-release reports (10)